colchicine - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.49 [0.19, 1.25]< 10%3 studies (3/-)93.2 %some concernnot evaluable moderatecrucial-
hospitalization for COVID19 or death 0.79 [0.61, 1.03]< 10%1 study (1/-)96.1 %lownot evaluable highcrucial-
clinical deterioration 0.11 [0.01, 1.08]< 10%1 study (1/-)97.0 %some concernnot evaluable moderateimportant-
hospitalization 0.79 [0.60, 1.04]< 10%1 study (1/-)95.6 %lownot evaluable highimportant-
ventilation 0.47 [0.23, 0.95]< 10%2 studies (2/-)98.3 %some concernnot evaluable moderateimportant-

safety endpoints 00

related AE (TRAE) 1.74 [1.50, 2.03]< 10%1 study (1/-)0.0 %lownot evaluable highimportant-
serious adverse events 0.77 [0.60, 1.00]< 10%1 study (1/-)97.4 %lownot evaluable highimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.